Alexandra Pietraszkiewicz1, Freekje van Asten2, Alan Kwong3, Rinki Ratnapriya1, Goncalo Abecasis3, Anand Swaroop1, Emily Y Chew4. 1. Neurobiology, Neurodegeneration and Repair Laboratory, National Eye Institute, National Institutes of Health, Bethesda, Maryland. 2. Neurobiology, Neurodegeneration and Repair Laboratory, National Eye Institute, National Institutes of Health, Bethesda, Maryland; Division of Epidemiology and Clinical Applications, National Eye Institute, National Institutes of Health, Bethesda, Maryland. 3. Biostatistics and Center for Statistical Genetics, University of Michigan, Ann Arbor, Michigan. 4. Division of Epidemiology and Clinical Applications, National Eye Institute, National Institutes of Health, Bethesda, Maryland. Electronic address: echew@nei.nih.gov.
Abstract
PURPOSE: To investigate the association of rare predicted loss-of-function (pLoF) variants within age-related macular degeneration (AMD) risk loci and AMD sub-phenotypes. DESIGN: Case-control study. PARTICIPANTS: Participants of AREDS, AREDS2, and Michigan Genomics Initiative. METHODS: Whole genome sequencing data were analyzed for rare pLoF variants (frequency <0.1%) in the regions of previously identified 52 independent risk variants known to be associated with AMD. Frequency of the rare pLoF variants in cases with intermediate or advanced AMD was compared with controls. Variants were assigned to the complement, extracellular matrix (ECM), lipid, cell survival, immune system, metabolism, or unknown/other pathway. Associations of rare pLoF variant pathways with AMD sub-phenotypes were analyzed using logistic and linear regression, and Cox proportional hazards models. MAIN OUTCOME MEASURES: Differences in rare pLoF variant pathway burden and association of rare pLoF variant pathways with sub-phenotypes within the population with AMD were evaluated. RESULTS: Rare pLoF variants were found in 298 of 1689 cases (17.6%) and 237 of 1518 controls (15.6%) (odds ratio [OR], 1.11; 95% confidence interval [CI], 0.91-1.36; P = 0.310). An enrichment of rare pLoF variants in the complement pathway in cases versus controls (OR, 2.94; 95% CI, 1.49-5.79; P = 0.002) was observed. Within cases, associations between all rare pLoF variants and choroidal neovascularization (CNV) (OR, 1.34; 95% CI, 1.04-1.73; P = 0.023), calcified drusen (OR, 1.33; 95% CI, 1.04-1.72; P = 0.025), higher scores on the AREDS Extended AMD Severity Scale (Standardized Coefficient Beta (β)=0.346 [0.086-0.605], P = 0.009), and progression to advanced disease (hazard ratio, 1.25; 95% CI, 1.01-1.55; P = 0.042) were observed. At the pathway level, there were associations between the complement pathway and geographic atrophy (GA) (OR, 2.17; 95% CI, 1.12-4.24; P = 0.023), the complement pathway and calcified drusen (OR, 3.75; 95% CI, 1.79-7.86; P < 0.001), and the ECM pathway and more severe levels in the AREDS Extended AMD Severity Scale (β = 0.62; 95% CI, 0.04-1.20; P = 0.035). CONCLUSIONS: Rare pLoF variants are associated with disease progression. Variants in the complement pathway modify the clinical course of AMD and increase the risk of developing specific sub-phenotypes. Published by Elsevier Inc.
RCT Entities:
PURPOSE: To investigate the association of rare predicted loss-of-function (pLoF) variants within age-related macular degeneration (AMD) risk loci and AMD sub-phenotypes. DESIGN: Case-control study. PARTICIPANTS: Participants of AREDS, AREDS2, and Michigan Genomics Initiative. METHODS: Whole genome sequencing data were analyzed for rare pLoF variants (frequency <0.1%) in the regions of previously identified 52 independent risk variants known to be associated with AMD. Frequency of the rare pLoF variants in cases with intermediate or advanced AMD was compared with controls. Variants were assigned to the complement, extracellular matrix (ECM), lipid, cell survival, immune system, metabolism, or unknown/other pathway. Associations of rare pLoF variant pathways with AMD sub-phenotypes were analyzed using logistic and linear regression, and Cox proportional hazards models. MAIN OUTCOME MEASURES: Differences in rare pLoF variant pathway burden and association of rare pLoF variant pathways with sub-phenotypes within the population with AMD were evaluated. RESULTS: Rare pLoF variants were found in 298 of 1689 cases (17.6%) and 237 of 1518 controls (15.6%) (odds ratio [OR], 1.11; 95% confidence interval [CI], 0.91-1.36; P = 0.310). An enrichment of rare pLoF variants in the complement pathway in cases versus controls (OR, 2.94; 95% CI, 1.49-5.79; P = 0.002) was observed. Within cases, associations between all rare pLoF variants and choroidal neovascularization (CNV) (OR, 1.34; 95% CI, 1.04-1.73; P = 0.023), calcified drusen (OR, 1.33; 95% CI, 1.04-1.72; P = 0.025), higher scores on the AREDS Extended AMD Severity Scale (Standardized Coefficient Beta (β)=0.346 [0.086-0.605], P = 0.009), and progression to advanced disease (hazard ratio, 1.25; 95% CI, 1.01-1.55; P = 0.042) were observed. At the pathway level, there were associations between the complement pathway and geographic atrophy (GA) (OR, 2.17; 95% CI, 1.12-4.24; P = 0.023), the complement pathway and calcified drusen (OR, 3.75; 95% CI, 1.79-7.86; P < 0.001), and the ECM pathway and more severe levels in the AREDS Extended AMD Severity Scale (β = 0.62; 95% CI, 0.04-1.20; P = 0.035). CONCLUSIONS: Rare pLoF variants are associated with disease progression. Variants in the complement pathway modify the clinical course of AMD and increase the risk of developing specific sub-phenotypes. Published by Elsevier Inc.
Authors: Robert J Klein; Caroline Zeiss; Emily Y Chew; Jen-Yue Tsai; Richard S Sackler; Chad Haynes; Alice K Henning; John Paul SanGiovanni; Shrikant M Mane; Susan T Mayne; Michael B Bracken; Frederick L Ferris; Jurg Ott; Colin Barnstable; Josephine Hoh Journal: Science Date: 2005-03-10 Impact factor: 47.728
Authors: Hannes Helgason; Patrick Sulem; Maheswara R Duvvari; Hongrong Luo; Gudmar Thorleifsson; Hreinn Stefansson; Ingileif Jonsdottir; Gisli Masson; Daniel F Gudbjartsson; G Bragi Walters; Olafur Th Magnusson; Augustine Kong; Thorunn Rafnar; Lambertus A Kiemeney; Frederieke E Schoenmaker-Koller; Ling Zhao; Camiel J F Boon; Yaojun Song; Sascha Fauser; Michelle Pei; Tina Ristau; Shirrina Patel; Sandra Liakopoulos; Johannes P H van de Ven; Carel B Hoyng; Henry Ferreyra; Yaou Duan; Paul S Bernstein; Asbjorg Geirsdottir; Gudleif Helgadottir; Einar Stefansson; Anneke I den Hollander; Kang Zhang; Fridbert Jonasson; Haraldur Sigurdsson; Unnur Thorsteinsdottir; Kari Stefansson Journal: Nat Genet Date: 2013-09-15 Impact factor: 38.330
Authors: Mingyao Li; Pelin Atmaca-Sonmez; Mohammad Othman; Kari E H Branham; Ritu Khanna; Michael S Wade; Yun Li; Liming Liang; Sepideh Zareparsi; Anand Swaroop; Gonçalo R Abecasis Journal: Nat Genet Date: 2006-08-27 Impact factor: 38.330
Authors: Rinki Ratnapriya; Xiaowei Zhan; Robert N Fariss; Kari E Branham; David Zipprer; Christina F Chakarova; Yuri V Sergeev; Maria M Campos; Mohammad Othman; James S Friedman; Arvydas Maminishkis; Naushin H Waseem; Matthew Brooks; Harsha K Rajasimha; Albert O Edwards; Andrew Lotery; Barbara E Klein; Barbara J Truitt; Bingshan Li; Debra A Schaumberg; Denise J Morgan; Margaux A Morrison; Eric Souied; Evangelia E Tsironi; Felix Grassmann; Gerald A Fishman; Giuliana Silvestri; Hendrik P N Scholl; Ivana K Kim; Jacqueline Ramke; Jingsheng Tuo; Joanna E Merriam; John C Merriam; Kyu Hyung Park; Lana M Olson; Lindsay A Farrer; Matthew P Johnson; Neal S Peachey; Mark Lathrop; Robert V Baron; Robert P Igo; Ronald Klein; Stephanie A Hagstrom; Yoichiro Kamatani; Tammy M Martin; Yingda Jiang; Yvette Conley; Jose-Alan Sahel; Donald J Zack; Chi-Chao Chan; Margaret A Pericak-Vance; Samuel G Jacobson; Michael B Gorin; Michael L Klein; Rando Allikmets; Sudha K Iyengar; Bernhard H Weber; Jonathan L Haines; Thierry Léveillard; Margaret M Deangelis; Dwight Stambolian; Daniel E Weeks; Shomi S Bhattacharya; Emily Y Chew; John R Heckenlively; Gonçalo R Abecasis; Anand Swaroop Journal: Hum Mol Genet Date: 2014-06-04 Impact factor: 6.150
Authors: Catherine Cukras; Elvira Agrón; Michael L Klein; Frederick L Ferris; Emily Y Chew; Gary Gensler; Wai T Wong Journal: Ophthalmology Date: 2010-01-15 Impact factor: 12.079
Authors: Felix Grassmann; Stuart Cantsilieris; Anja-Sabrina Schulz-Kuhnt; Stefan J White; Andrea J Richardson; Alex W Hewitt; Brendan J Vote; Denise Schmied; Robyn H Guymer; Bernhard H F Weber; Paul N Baird Journal: J Neuroinflammation Date: 2016-04-18 Impact factor: 8.322
Authors: Bärbel Rohrer; Ashley Frazer-Abel; Anthony Leonard; Rinki Ratnapriya; Tyson Ward; Alexandra Pietraszkiewicz; Elizabeth O'Quinn; Katherine Adams; Anand Swaroop; Bethany Jacobs Wolf Journal: Mol Vis Date: 2019-02-08 Impact factor: 2.367
Authors: Rinki Ratnapriya; İlhan E Acar; Maartje J Geerlings; Kari Branham; Alan Kwong; Nicole T M Saksens; Marc Pauper; Jordi Corominas; Madeline Kwicklis; David Zipprer; Margaret R Starostik; Mohammad Othman; Beverly Yashar; Goncalo R Abecasis; Emily Y Chew; Deborah A Ferrington; Carel B Hoyng; Anand Swaroop; Anneke I den Hollander Journal: Hum Mol Genet Date: 2020-07-29 Impact factor: 6.150